Nowadays nonalcoholic fatty liver disease is one of the most widespread diseases in hepatology, leading to life deterioration, invalidization and death rates that first of all is caused by high risk of progressing with development of hepatic insufficiency and hepatocellular carcinoma. The aim of the present review is the analysis of the literature information specifying in features of pathogenetic mechanisms of nonalcoholic fatty liver disease, diagnostik and patients managment.

1. AGA. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. – 2012. – Vol. 142. – P. 1592–1609.

2. Ludwig, J. Nonalcoholic steatohepatitis / J. Ludwig // Mayo Clin. Proc. – 1980. – Vol.55. – P.434 – 438.

3. Trombini, P. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons / P. Trombini, A. Piperno // J. Hepatol. – 2007. – Vol. 46. – P. 549–552.

4. Reddy, J. K. Nonalcoholic steatosis and steatohepatitis. Peroxisomal b-oxidation, PPAR-a and steatohepatitis / J. K. Reddy // Am. J. Physiol. Gastrointest. Liver Physiol. – 2001. – Vol. 282. – P. 1333 – 1339.

5. Lipid peroxidation and tissue damage / C. Mylonas [et al.] // In Vivo. – 1999. – Vol. 13. – P.295–309.

6. Insulin resistance-associated hepatic iron overload / M. H. Mendler [et al.] // Gastroenterology – 1999. – Vol. 117. – P. 1155–1163.

7. Diehl, A. M. Nonalcoholic steatosis and steatohepatitis. Nonalcoholic liver disease abnormalities in macrophage function and cytokines / A. M. Diehl // Am. J. Physiol. Gastrointest. Liver Physiol. – 2002. – Vol. 282. – P. 1–5.

8. Силивончик. Н. Н. Неалкогольная жировая болезнь печени: возможности лечения. // Мед. новости. – 2008. – № 8. – С. 8–12.

9. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple Markers / Guha I. N. [et al.] // Hepatology – 2008. – Vol. 47. – P. 455–460.

10. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? / McPherson S [et al.] // Eur J Gastroenterol. Hepatol. – 2013. – Vol. 25. – P. 652–658.

11. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease / Wong V. W. [et al.] // Hepatology. – 2010. – Vol. 51. – P. 454–462.

12. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations / Castera L. [et al] // Hepatology. – 2010. – Vol. 51. – P. 828–835.

13. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease / Wong V. W. [et al.] // Am J Gastroenterol. – 2012. – Vol. 107. – P. 1862–1871.

14. EASL–EASD–EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease / EASL–EASD– EASO // J. Gastroenterol. – 2016. – Vol. 64. – P. 1388–1402

15. La Brecque D. World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2012.

16. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment / Ersoz G. [et al.] // Turk. J. Gastroenterol. – 2005. – Vol. 16. – P. 124–128.

17. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis / Harrison S. A. [et al.] // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 2485–2490.

18. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis / Sanyal A. J. [et al.] // Clin. Gastroenterol. Hepatol. – 2004. – Vol. 2. – P. 1107–1115.